FAST NEWS: Connect Biopharma Plunges Despite Positive Drug Trial Results
The latest: Connect Biopharma (CNTB.US) said on Tuesday its CBP-201 drug candidate achieved all primary and key secondary endpoints in the primary analysis population for a 16-week pivotal trial of…
RELATED ARTICLES
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK -
BRIEF: Everest unveils positive results for kidney drug EVER001 in Phase 1b/2a trial
1952.HK
- Pateo Connect revs up for IPO, belching widening losses and slumping margins
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Inmagene Bio charts backdoor to U.S. listing with offshore acquisition
IKNA.US
